Deals channel feed – Endpoints News

Deals channel feed

Cancer giant Roche splashes into cell therapy with $3B+ Adaptimmune deal for off-the-shelf drugs

4 years ago

Private equity, sovereign wealth fund ally on an $8B buyout aimed at taking rare disease player private

4 years ago

An FTC review of the Sanofi/Translate merger has a new deadline after agency calls for more time

4 years ago

Antiviral nasal drop maker does the Nasdaq shuffle as part of minor SPAC reverse merger

4 years ago

Luca Santarelli's VectivBio buys out small Massachusetts biotech, redoubling focus on metabolic disease

4 years ago

Playing a surprisingly hot hand, BeyondSpring nails a $200M China deal in wake of a pivotal success

4 years ago

ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal

4 years ago

Albert Bourla picks a new dealmaker to lead the hunt for more drugs to swell Pfizer’s pipeline

4 years ago

Eli Lilly keeps its foot on dealmaking pedal, recruiting Carolyn Bertozzi's protein degradation tech for $1.6B+

4 years ago

Exclusive: Roche tees up $3B+ for Shape's RNA editing platform, with the bold promise of 'one-time' cures for Alzheimer's, Parkinson's

4 years ago

Vertex goes back to gene-editing partner — and science founder Feng Zhang — to add $1.2B deal on engineered cell therapies

4 years ago

Genevant scores with Takeda again as LNPs continue to attract interest for RNA therapy

4 years ago

Pfizer doles out $2.3B for blood cancer player to flesh out its end-of-decade oncology portfolio

4 years ago

What antitrust challenge? Illumina completes $8B Grail buyout while FTC, EU probes remain ongoing

4 years ago

Verily scoops up a fellow software maker as Amy Abernethy scales its clinical trials platform

4 years ago

InnoCare bags Chinese rights to Incyte CAR-T rival Monjuvi in bid to expand in-house pipeline

4 years ago

Boehringer Ingelheim scraps $600M+ lung cancer program with CureVac, as the biotech preps its second Covid-19 shot

4 years ago

Inside the deal: Sanofi flipped from sell-off to merger in lead up to $3.2B Translate buyout

4 years ago

Vectura board says it will unanimously back a Philip Morris takeover

4 years ago

Out to revamp plant-based drug manufacturing, Antheia locks in partnership with synthetic biology giant Ginkgo

4 years ago

The Carlyle Group axes auction by calling its $1.3B bid for Vectura 'final' — now the ball is in Philip Morris' court

4 years ago

As AbbVie and Soliton shake hands on a $550M merger, the FTC says 'not so fast'

4 years ago

A decades-old glaucoma drug tossed aside by Pfizer gets a new life at a small biotech

4 years ago

ADC experts at Seagen find a $2.6B HER2 gem in China that they think can go where Enhertu, Kadcyla can't

4 years ago

First page Previous page 70 71 727374 75 76 Next page Last page